Natco Pharma Limited — Investor Meet, 29-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

NATCO Pharma is acquiring a 35.75% stake in South African Adcock Ingram for approximately 2,000 Cr, with plans to delist it. This "monumental acquisition" diversifies NATCO's global footprint, adding a stable African market. Management expects revenue synergies by leveraging NATCO's R&D pipeline, especially in the Prescription business, to improve Adcock's 14-15% margins. NATCO will have one-third of Adcock's board seats. The company plans further large acquisitions for global diversification and to strengthen its portfolio, aiming to reduce reliance on the US market. Post-acquisition, NATCO's cash balance will be around INR 1,500 Cr.